Compugen has been granted a patent for a novel pharmaceutical combination that includes an ILDR2 antagonist and one or more other therapeutically active compounds. The ILDR2 antagonist can be an anti-ILDR2 antibody or a modified antibody format with specific binding properties. The patent also covers the specific sequences of the CDR heavy chain and CDR light chain of the ILDR2 antagonist. GlobalData’s report on Compugen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Compugen, personalized cancer vaccines was a key innovation area identified from patents. Compugen's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a pharmaceutical combination with ildr2 antagonist
A recently granted patent (Publication Number: US11655297B2) discloses a pharmaceutical combination for the treatment of various conditions. The combination comprises an ILDR2 antagonist, which can be an anti-ILDR2 antibody or a modified antibody format. The ILDR2 antagonist has specific binding properties defined by certain CDR heavy chain and CDR light chain sequences. Optionally, the combination can also include other therapeutically active compounds such as a PD-L1 antagonist, a taxane or taxane derivative, a vaccine, a CpG oligodeoxynucleotide, or a compound targeting c4.4A.
The patent claims also cover the administration of the ILDR2 antagonist and other therapeutically active compounds in the same dosage unit or in individual dosage units. The combination can be administered simultaneously or sequentially, depending on the specific treatment protocol.
Furthermore, the patent describes an anti-ILDR2 antibody with specific CDR heavy chain and CDR light chain sequences. The antibody can be a fragment or derivative thereof, or a modified antibody format. The sequences of the heavy chain and light chain variable regions of the antibody are defined and are highly similar to specific reference sequences.
The patent also discloses an antibody-drug conjugate comprising the ILDR2 antibody or its fragments or derivatives. Additionally, it covers isolated nucleic acid sequences encoding the ILDR2 antibody, vectors containing these sequences, and isolated cells expressing the ILDR2 antibody.
The patent further describes specific combinations of CDR heavy chain and CDR light chain sequences that can be used to create ILDR2 antibodies with ILDR2 binding properties. It also includes combinations of heavy chain and light chain variable region sequences for the ILDR2 antibody.
Finally, the patent lists specific anti-ILDR2 antibodies, including 61-02.C05, 56-02.E08, 74-15.G09, and 59-08.B02, as part of the invention.
Overall, this granted patent provides a comprehensive disclosure of a pharmaceutical combination involving an ILDR2 antagonist and other therapeutically active compounds, as well as specific ILDR2 antibodies and their derivatives. These inventions have the potential to advance the treatment of various conditions and diseases.